Floatz logo

Ezetimibe

Ischemic Stroke

Beijing Tiantan HospitalSmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
65/ 100

Competitive context

210 Active assets in the Ischemic Stroke cohort.

Asset / SponsorPhaseRating
Ticagrelor
Sichuan Provincial People's Hospital
Phase 4BBB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Stanford University
Phase 4BBB
Compound Edaravone
Nanfang Hospital, Southern Medical University
Phase 4BBB
Tenecteplase
Hackensack Meridian Health
Phase 4BBB
3-N-BUTYLPHTHALIDE
Nanfang Hospital, Southern Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

Ezetimibe is also rated in:

HypercholesterolemiaDormant
BBB
Indicative ·
79 / 100
View asset →
coronary artery disorderDormant
BBB
Indicative ·
76 / 100
View asset →
inherited lipid metabolism disorderDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →